PMID- 30221571
OWN - NLM
STAT- MEDLINE
DCOM- 20190704
LR  - 20190704
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 30
IP  - 4
DP  - 2019 Jun
TI  - Real-world data on the efficacy and safety of apremilast in Japanese patients 
      with plaque psoriasis.
PG  - 383-386
LID - 10.1080/09546634.2018.1525480 [doi]
AB  - Background: Real-world data differ from clinical trial data. Although some 
      real-world data regarding apremilast use for psoriasis treatment has been 
      reported in Western countries, no such data has been reported in Asian countries. 
      Objective: To study the efficacy, including Psoriasis Area and Severity Index 
      (PASI) and drug survival, and safety of apremilast in Japanese patients with 
      psoriasis. Methods: Data on all the patients treated with apremilast in Kurume 
      University Hospital between May 2017 and June 2018 were retrieved, with June 30 
      2018, as the data lock date. Efficacy was analyzed by PASI50, PASI75, and PASI90; 
      drug survival by Kaplan-Meier analysis; and drug safety by the proportion of 
      adverse events (AEs). Results: Fourteen of 42 (33.3%) patients achieved 
      PASI75/90; 16 (32%) patients had discontinued apremilast by the data lock date. 
      Drug survival at week 28 was 70%. No serious AEs were reported; the most 
      prevalent one was loose stools/diarrhea (60%), followed by nausea (38%). The most 
      common reason for apremilast discontinuation was primary/secondary failure. 
      Conclusions: Apremilast is safe and effective in Japanese patients with 
      psoriasis. Higher occurrence of loose stools/diarrhea was noted in our cohort 
      than that reported in Western real-world studies on apremilast.
FAU - Ohata, Chika
AU  - Ohata C
AUID- ORCID: 0000-0001-8341-7300
AD  - a Department of Dermatology , Kurume University School of Medicine , Fukuoka , 
      Japan.
FAU - Ohyama, Bungo
AU  - Ohyama B
AD  - a Department of Dermatology , Kurume University School of Medicine , Fukuoka , 
      Japan.
FAU - Kuwahara, Fumi
AU  - Kuwahara F
AD  - a Department of Dermatology , Kurume University School of Medicine , Fukuoka , 
      Japan.
FAU - Katayama, Eri
AU  - Katayama E
AD  - a Department of Dermatology , Kurume University School of Medicine , Fukuoka , 
      Japan.
FAU - Nakama, Takekuni
AU  - Nakama T
AD  - a Department of Dermatology , Kurume University School of Medicine , Fukuoka , 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20181008
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - UP7QBP99PN (apremilast)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy
MH  - Thalidomide/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Apremilast
OT  - Japan
OT  - drug survival
OT  - psoriasis
EDAT- 2018/09/18 06:00
MHDA- 2019/07/05 06:00
CRDT- 2018/09/18 06:00
PHST- 2018/09/18 06:00 [pubmed]
PHST- 2019/07/05 06:00 [medline]
PHST- 2018/09/18 06:00 [entrez]
AID - 10.1080/09546634.2018.1525480 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2019 Jun;30(4):383-386. doi: 10.1080/09546634.2018.1525480. 
      Epub 2018 Oct 8.